| |
GEOVAX LABS GRANTED ALLOWANCE BY FDA TO START PHASE 1 CLINICAL TRIAL FOR HIV/AIDS THERAPEUTIC VACCINE - attached press release
|
| |
| |
Download the PDF here
Company Will Begin Non-Blinded Study in HIV Infected Individuals
Who Started Drug Treatment During Their First Year of Infection
GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA (US Food and Drug Administration) to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV (Human Immunodeficiency Virus). The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection. An unmet need exists in the market for a HIV therapeutic vaccine if it can reduce the need for expensive and poorly tolerated lifelong oral medications currently available to infected individuals.
| |
| |
| |
|
|
|
